ArticleMolecular neurodegeneration2016
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.
Article in Molecular neurodegeneration, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.Journal of Alzheimer's disease : JAD · 2017Trial
- Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.Alzheimer's research & therapy · 2024Article
- Association of modified dementia risk score with cerebrospinal fluid biomarkers and cognition in adults without dementia.Frontiers in aging neuroscience · 2024Article
- A Growing Link between Circadian Rhythms, Type 2 Diabetes Mellitus and Alzheimer's Disease.International journal of molecular sciences · 2022Review
- Tau kinetics in Alzheimer's disease.Frontiers in aging neuroscience · 2022Article
- P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
- Serum tau concentration after diving - an observational pilot study.Diving and hyperbaric medicine · 2019Article
- Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2018Review
- Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.Molecular brain · 2018Article
- The "glymphatic" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation?FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Review
- BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology.Molecules (Basel, Switzerland) · 2017Review
- Diurnal oscillation of CSF Aβ and other AD biomarkers.Molecular neurodegeneration · 2017Article
- Cerebrospinal fluid in Alzheimer's: A precious tool.Oncotarget · 2017Article
- Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?PloS one · 2017Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebrospinal fluid (CSF) biomarkers have gained increasing importance in the diagnostic work-up of Alzheimer's disease (AD). The core CSF biomarkers related to AD pathology (Aβ42, t-tau and p-tau) are currently used in CSF diagnostics, while candidate markers of amyloid metabolism (Aβ38, Aβ40, sAPPα, sAPPβ), synaptic loss (neurogranin), neuroinflammation (YKL-40), neuronal damage (VILIP-1) and genetic risk (apolipoprotein E) are undergoing evaluation. Diurnal fluctuation in the concentration of CSF biomarkers has been reported and may represent a preanalytical confounding factor in the laboratory diagnosis of AD. The aim of the present study was to investigate the diurnal variability of classical and candidate CSF biomarkers in a cohort of neurosurgical patients carrying a CSF drainage.
methodSamples were collected from a cohort of 13 neurosurgical patients from either ventricular (n = 6) or lumbar (n = 7) CSF drainage at six time points during the day, 1-7 days following the neurosurgical intervention. Concentrations of the core biomarkers were determined by immunoassays.
resultsAlthough absolute values largely varied among subjects, none of the biomarkers showed significant diurnal variation. Site of drainage (lumbar vs. ventricular) did not influence this result. The different immunoassays used for tau and Aβ markers provided similar results.
conclusionTime of day at CSF collection does not ultimately affect the concentration levels of classical and candidate AD biomarkers. Similar trends were found when using different immunoassays, thus corroborating the consistency of the data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.